Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE, Grieger JC, Govindasamy L, Agbandje-McKenna M, Xiao X, Samulski RJ.
Bowles DE, et al. Among authors: grieger jc.
Mol Ther. 2012 Feb;20(2):443-55. doi: 10.1038/mt.2011.237. Epub 2011 Nov 8.
Mol Ther. 2012.
PMID: 22068425
Free PMC article.
Clinical Trial.